retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide to Weight Loss, Appetite Control & Metabolic Reset Eli Lilly's retatrutide shows promising

The PA form requires documentation of three to six months of lifestyle intervention with weight or A1c data

Leah Joseph, MD, FACP , provides expert guidance to help you choose the best treatment for your needs

86,87 Differing from the effects observed in T2DM, the therapeutic efficacy of dulaglutide for MASLD is not particularly compelling based on current statistics

Glucagon-like peptide 1 and its analogs in diabetes therapy

Activation there reduces food intake, and it is this central action, as much as any peripheral effect, that drives the weight loss seen with GLP-1 drugs

Prevalence and sociodemographic correlates of DSM-5 eating disorders in the Australian population